For the quarter ending 2026-03-31, VTVT had $9,154K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) before noncontrolling interest | 24,134 | -7,138 | -10,345 | -13,597 |
| Depreciation expense | 1 | 2 | 2 | 12 |
| Loss on disposal of property and equipment | - | -6 | - | - |
| Loss from g42 promissory note early redemption | - | 0 | - | - |
| Non-cash interest income | - | 0 | - | - |
| Share-based compensation expense | 1,388 | 1,025 | 1,007 | 1,743 |
| Realized gain on sale of investment in reneo pharmaceuticals, inc | - | 0 | - | - |
| Impairment of investments in anteris bio, inc | - | 0 | - | - |
| Change in fair value of warrants-Related Party | -24 | 47 | 6 | -26 |
| Change in fair value of warrants-Nonrelated Party | -9 | 70 | 34 | 5 |
| Prepaid expenses | -222 | -97 | 481 | -833 |
| Other current assets | -17 | 106 | 19 | -82 |
| Other assets | 0 | -24 | -34 | -67 |
| Accounts payable and accrued expenses | 264 | -3,246 | 4,587 | 189 |
| Contract liabilities | -16,839 | 0 | - | - |
| Other liabilities | 0 | -32 | -47 | -90 |
| Net cash provided by (used in) operating activities | 9,154 | -9,251 | -5,222 | -10,782 |
| Proceed from sale of investments in reneo pharmaceuticals, inc | - | 0 | - | - |
| Net cash provided by (used in) investing activities | - | 0 | - | - |
| Proceeds from sale of class a common stock, pre-funded and common warrants, net of offering costs | - | 0 | 77,476 | - |
| Proceeds from sale of class a common stock and pre-funded warrants, net of offering costs | - | 0 | 0 | 0 |
| Proceeds from issuance of class a common stock, net of offering costs | - | 0 | 0 | - |
| Proceeds from sale of class a common stock to collaboration partner, net of offering costs | - | 0 | - | - |
| Proceeds from the exercise of stock options | - | 7 | 0 | 9 |
| Taxes paid related to net share settlement of equity awards | - | 0 | 0 | 51 |
| Proceeds from debt issuance | - | 0 | 392 | - |
| Repayment of notes payable | - | 328 | 64 | 0 |
| Net cash provided by financing activities | - | -321 | 77,804 | -42 |
| Net increase (decrease) in cash and cash equivalents | 9,154 | -9,572 | 72,582 | -10,824 |
| Total cash and cash equivalents, beginning of period | 88,932 | 98,504 | 36,746 | - |
| Total cash and cash equivalents, end of period | 98,086 | 88,932 | 98,504 | - |
vTv Therapeutics Inc. (VTVT)
vTv Therapeutics Inc. (VTVT)